Freeline_Logo_Red_RGB.jpg
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
04 oct. 2023 07h00 HE | Freeline Therapeutics Holdings plc
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher
Freeline_Logo_Red_RGB.jpg
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
15 août 2023 07h00 HE | Freeline Therapeutics Holdings plc
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase...
Freeline_Logo_Red_RGB.jpg
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
25 juil. 2023 07h30 HE | Freeline Therapeutics Holdings plc
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated...
Freeline_Logo_Red_RGB.jpg
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
26 juin 2023 07h30 HE | Freeline Therapeutics Holdings plc
FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing in people with Gaucher disease Company expects to report...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
15 nov. 2022 07h00 HE | Freeline Therapeutics Holdings plc
Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies ...
Freeline_Logo_Red_RGB.jpg
Freeline to Present at the Stifel Healthcare Conference
09 nov. 2022 07h00 HE | Freeline Therapeutics Holdings plc
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
09 août 2022 07h00 HE | Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
TIP_link_300x300.jpg
Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The Insight Partners
22 juil. 2022 07h35 HE | The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Freeline_Logo_Red_RGB.jpg
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
10 mai 2022 16h01 HE | Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline_Logo_Red_RGB.jpg
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
02 mai 2022 17h10 HE | Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...